Clinical Trials Logo

Epidermolysis Bullosa Simplex clinical trials

View clinical trials related to Epidermolysis Bullosa Simplex.

Filter by:

NCT ID: NCT06073132 Recruiting - Clinical trials for Generalized Epidermolysis Bullosa Simplex

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Start date: April 4, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.

NCT ID: NCT05062070 Completed - Clinical trials for Epidermolysis Bullosa Simplex

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

TAMES
Start date: May 5, 2022
Phase: Phase 1
Study type: Interventional

TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with severe epidermolysis bullosa simplex (i.e., EBS-Dowling Meara). A total of 10, severe EBS patients, males and females ages 18 years and older, will be enrolled. Patients will apply TolaSure and Vehicle Gel once-daily for a maximum of 10 weeks.

NCT ID: NCT05033574 Active, not recruiting - Clinical trials for Epidermolysis Bullosa

The State of Sexual Development in Children With Inherited Epidermolysis Bullosa

Start date: December 8, 2020
Phase:
Study type: Observational

The aim of the study is to determine the state of sexual development in patients with inherited epidermolysis bullosa; the study is planned to include boys and girls aged 8 to 18 years with a diagnosis of epidermolysis bullosa simplex, junctional epidermolysis bullosa, Kindler syndrome.

NCT ID: NCT04908215 Completed - Clinical trials for Epidermolysis Bullosa Dystrophica

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of INM-755 (cannabinol) cream and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with epidermolysis bullosa (EB).

NCT ID: NCT04213703 Recruiting - Clinical trials for Epidermolysis Bullosa

A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT03472287 Completed - Clinical trials for Dystrophic Epidermolysis Bullosa

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Start date: May 18, 2018
Phase: Phase 1
Study type: Interventional

A pharmacokinetic (PK) study in 16-20 EB subjects to be allocated to two cohorts. Cohort 1 to include 8-10 subjects (ages 12 yrs and older); Cohort 2 to include 8-10 subjects (ages 6 months-11 yrs, inclusive). Cohort 2 only included subjects 4 yrs and older. Serial PK blood sampling collected on Days 1 and 10. Analyses were performed to determine the concentrations of diacerein and rhein.

NCT ID: NCT03453632 Recruiting - Clinical trials for Epidermolysis Bullosa Simplex

Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex

EBTox
Start date: June 14, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators hypothesize that palmar injections of botulinic toxin, via an inhibition of the sudation, would limit the occurrence of blisters in localized epidermolysis bullosa simplex (LEBS).

NCT ID: NCT03389308 Completed - Clinical trials for Epidermolysis Bullosa

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.

NCT ID: NCT03269474 Recruiting - Healthy Clinical Trials

Computational Drug Repurposing for All EBS Cases

Start date: November 28, 2017
Phase:
Study type: Observational

The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.

NCT ID: NCT03154333 Terminated - Clinical trials for Epidermolysis Bullosa Simplex

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.